medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (3)

Obtaining a mouse IgG1 version of rituximab to detect the human CD20 molecule

Harteman ÁO, Casadesus PAV, Mateo ARCM, López-Requena A, Sosa AK, Dorvignit PD, Rodríguez OT, Cedeño AM, Hernández GT

Language: Spanish
References: 15
Page: 1-18
PDF size: 580.42 Kb.


ABSTRACT

Introduction: Rituximab, chimeric antibody specific for human CD20 molecule, has been widely used in the treatment of several B-cell linfoproliferative disorders. For the selection of patients with the greatest potential to benefit from the therapy with rituximab, a number of techniques using monoclonal antibodies have been developed to detect the CD20 molecule. Objective: To obtain and to characterize a mouse IgG1 recombinant antibody, specific for human CD20, that contains the variable regions of rituximab. Methods: The lentiviral transduction of human embryonic kidney cells (HEK293) was used for the stable expression of the recombinant antibody. The immunochemical characterization of the antibody was performed by Western Blot and the recognition of CD20 was evaluated by immunohistochemistry and flow cytometry. Results: We generated the antibody 1F5, able to recognize by flow cytometry the CD20 molecule expressed on lymphoid human cell lines, as well as peripheral blood mononuclear cells from healthy donors and patients with B-cell lymphoproliferative disorders. However, 1F5 antibody detected the CD20 molecule on fresh tissues, but not on formalin-fixed paraffin embedded tissues,by immunohistochemistry. Conclusions: This work suggests the potential use of 1F5 antibody for the measurement of CD20 expression by flow cytometry in patients with B-cell leukemias or B-cell lymphomas in phase of leukemization. This could complement the studies to ensure the appropriate selection of patients for the treatment with rituximab.


REFERENCES

  1. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107-14.

  2. Cohen MD and Keystone E. Rituximab for Rheumatoid Arthritis. Rheumatol Ther. 2015; 2:99–111.

  3. Rydén-Aulin M, , Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, et al.Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science & Medicine. 2016;3:e000163.

  4. Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016; 87:2074–81.

  5. Rasheed A, Samad A, Raheem A, Hirani S, and Shabbir-Moosajee M.,CD20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab. Asian Pac J Cancer Prev.2018;19(2):331-5.

  6. Plasencia CA. Obtención de un clon de células CHO-K1 productor de un anticuerpo biespecífico y evaluación de su actividad biológica. (Tesis de Grado). Universidad de La Habana, La Habana. 2017.

  7. Dorvignit D, Palacios JL, Merino M, Hernandez T, Sosa K, Casaco A, et al. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study. MAbs. 2012;4(4):488-96.

  8. Kloboves Prevodnik V, Horvat M, Lavrencak J, Jezersek Novakovic B. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma. Oncol Rep. 2010; 24:1101–7.

  9. Tokunaga T, Tomita A, Sugimoto K, et al. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci. 2014;(105):35–43.

  10. Klein Ch, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner K-P, Umaña P and Niederfellner G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22–33.

  11. Mason DY, Comans-Bitter MW, Cordell J, Verhoeven MA and van Dongent JJM. Antibody L26 Recognizes an Intracellular Epitope on the B-Cell-Associated CD20 Antigen.American J Pathol. 1990;136(6):1215-22.

  12. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51(1):15-24.

  13. Baer WH II, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: A physician survey. Pharmaceuticals (Basel). 2014;7:530–44.

  14. Brown J, Cymbalista F, Sharman J, Jacobs I, Nava-Parada P, Mato A. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. Oncologist. 2017;22:1–9.

  15. Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009; 113(16):3773-80.




2020     |     www.medigraphic.com